Voluntary ex ante transparency notice
Directive 2014/24/EU
Section I: Contracting
entity
I.1) Name and addresses
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
2nd Floor Woodland House
Cardiff
CF144TT
UK
Contact person: Ryan James
Telephone: +44 2921836442
E-mail: ryan.james3@wales.nhs.uk
NUTS: UK
Internet address(es)
Main address: http://nwssp.nhs.wales/ourservices/procurement-services/
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
Reference number: CAV-STA (2021/2022) 9
II.1.2) Main CPV code
33696500
II.1.3) Type of contract
Supplies
II.1.4) Short description
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient.
Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
232 200.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKL22
Main site or place of performance:
All Wales Medical Genomics Service, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW
II.2.4) Description of the procurement
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient.
The test has continued to grow in demand across Wales for an established DPYD service and as a consequence AWMGL is now required to advertise their intention award a contract to Yourgene Health UK without prior advertisement.
The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons;
The test has already been validated by the laboratory as it has been used for a number of years, therefore meets the standards required to deliver the service. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the laboratory and would be extremely detrimental to patient care.
The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing.
The equipment needed for the test is already in place. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment.
Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test.
Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above)
NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGL, for the supply of a The Elucigene DPYD assay provided by Yourgene Health UK Limited, for the unique reasons outlined above. The contract is estimated to commence in July 2021, for a period of two years (to be awarded for 12 months with the option to extend for a further 12 months) for estimated quantity of 144 kits (3600 samples) per annum. The contract will include all associated services.
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition
Justification for selected award procedure:
The procurement falls outside the scope of application of the Directive
Explanation:
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient.
The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons;
The test has already been validated in the lab and is confirmed as being suitable for use. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the lab and be extremely detrimental to patient care.
The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing.
The equipment needed for the test is already in place and maintained. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment.
Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test.
Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above)
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section V: Award of contract/concession
Contract No: CAV-STA (2021/2022) 9
V.2 Award of contract/concession
V.2.1) Date of conclusion of the contract/concession
01/06/2021
V.2.2) Information about tenders
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
Yourgene Health
Nelson Street
Manchester
M139NQ
UK
Telephone: +44 7584917415
NUTS: UKD33
The contractor is an SME:
No
V.2.4) Information on value of the concession and main financing terms (excluding VAT)
Total value of the concession/lot:
232 200.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111498.
(WA Ref:111498)
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.4.3) Review procedure
Precise information on deadline(s) for review procedures:
The Authority will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract. Should additional information be required from the addressee in section 1.1 Ryan James (ryan.james3@wales.nhs.uk).
The Contracting Authority will enter into this Contract following a minimum 10 day calendar day standstill period starting on the day after this notice is published on Find a Tender. If legal proceedings are commenced in relation to the contract award, it will be necessary to suspend the award of the contract pending further order of the Court, or the authority may voluntarily decide (at its discretion) to suspend the award of contract whilst any outstanding queries are dealt with. We will not be liable for any costs or losses incurred by you as a result of any suspension of the contract award or as a result of any other action made necessary by any challenge.
VI.5) Date of dispatch of this notice
16/06/2021